Continuous improvement of FEV 1 in severe eosinophilic asthmatics on anti‐interleukin‐5 therapy
Allergy · 2024
DOI: 10.1111/all.16139 ↗Kurz gefasst
Leserbrief in der Zeitschrift Allergy, 2024. Verfasst von Alain Michils und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chest Department, Erasme University Hospital, Université libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Asthma, Interleukin-5, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: Chiesi Pharmaceuticals, Chiesi Farmaceutici.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chest Department, Erasme University Hospital, Université libre de Bruxelles, Brussels, Belgium.
- Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Alain Van Muylem
Förderung
- Chiesi Pharmaceuticals
- Chiesi Farmaceutici
Zitieren
APA
Michils, A., Makhoul, J. P., Blekic, N., Haccuria, A., Perez-Bogerd, S., Malinovschi, A., & Van Muylem, A. (2024). Continuous improvement of FEV 1 in severe eosinophilic asthmatics on anti‐interleukin‐5 therapy. Allergy. https://doi.org/10.1111/all.16139
Vancouver
Michils A, Makhoul JP, Blekic N, Haccuria A, Perez-Bogerd S, Malinovschi A, et al. Continuous improvement of FEV 1 in severe eosinophilic asthmatics on anti‐interleukin‐5 therapy. Allergy. 2024. doi:10.1111/all.16139
BibTeX
@article{Michils2024,
author = {Michils, Alain and Makhoul, Jean-Pierre and Blekic, Nathan and Haccuria, Amaryllis and Perez-Bogerd, Silvia and Malinovschi, Andreï and Van Muylem, Alain},
title = {Continuous improvement of FEV 1 in severe eosinophilic asthmatics on anti‐interleukin‐5 therapy},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16139}
}
EUVIMED